Computer Modeling of Drug Distribution after Intravitreal Administration
Intravitreal injection (IVI) is the most common treatment for eye posterior segment diseases such as endopthalmitis, retinitis, age-related macular degeneration, diabetic retinopathy, uveitis, and retinal detachment. Most of the drugs used to treat vitreoretinal diseases, have a narrow concentration range in which they are effective, and may be toxic at higher concentrations. Therefore, it is critical to know the drug distribution within the eye following intravitreal injection. Having knowledge of drug distribution, ophthalmologists can decide on drug injection frequency while minimizing damage to tissues. The goal of this study was to develop a computer model to predict intraocular concentrations and pharmacokinetics of intravitreally injected drugs. A finite volume model was created to predict distribution of two drugs with different physiochemical properties in the rabbit eye. The model parameters were obtained from literature review. To validate this numeric model, the in vivo data of spatial concentration profile from the lens to the retina were compared with the numeric data. The difference was less than 5% between the numerical and experimental data. This validation provides strong support for the numerical methodology and associated assumptions of the current study.
Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1327700Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1926
 J. E. Chastain, " General considerations in ocular drug delivery," in: Ophthalmic Drug Delivery Systems, A. K. Mitra, Ed. New York: Marcel Dekker, 2003, p. 76.
 E. Eljarrat-Binstock E, J. Pe'er and A. J. Domb, " New techniques for drug delivery to the posterior eye segment," Pharm Res. , vol. 27 (4). 2010, pp. 530-543.
 G. A. Peyma, M. E. Lad and M. D. Moshfeghi, "Intravitreal injection of therapeutic agents," Retina, The journal of retina and vitreous diseases, vol. 29(7) 2009, pp. 875-911.
 C. Duraira, J. C. Sha, S. Senapati and U. B. Kompella, "Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR)," Pharm. Res., vol. 26(5) 2009, pp. 1236-1260.
 M. S. Sta, J. X, T. W. Randolph and V. H. Barocas, "Computer simulation of convective and diffusive transport of controlled release drugs in the vitreous humor," Pharm. Res., vol. 20,2003, pp. 96-102.
 S. Friedrich, Y. L. Cheng and B. Saville, "Finite element modelling of drug distribution in the vitreous humor of the rabbit eye," Ann. Biomed. Eng. vol. 25,1997, pp. 303-314.
 J. Xu, J. J Heys, V. H.Barocas and T. W. Randolph, "Permeability and diffusion in vitreous humor: implications for drug delivery," Pharm. Res., vol. 17, 2000, pp. 664-669.
 E. N. Marieb and K. Hoehn, Human Anatomy & Physiology, 7th ed., Pearson Education Inc,2006.
 H. Davson,. in: The Eye, 2nd ed., H. Davson, Ed., New York: Academic Press, 1969, pp. 88-92
 J. Kathawate and S. Acharya, "Computational modeling of intravitreal drug delivery in the vitreous chamber with different vitreous substitutes," International Journal of Heat and Mass Transfer, vol. 5, 2008, pp. 5598-5609.
 P. L. Kaufman and A. Alm, Adlers-s Physiology of the Eye, 10th ed. Mosby Year book,2003.
 P. A. Pearson, G. J. Jaffe, D. F. Martin, G. J. Cordahi, H. Grossniklaus, E. T. Schmeisser and P. Ashton, "Evaluation of a delivery system providing long-term release of cyclosporine,"Arch. Ophthalmol. vol. 114, 1996, pp. 311-317.
 I. Fatt and B. Hedbys, "Flow of water in the sclera,"Exp. Eye Res. Vol. 10, 1970, pp. 243-249.
 M. Araie and D. M. Maurice, "The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways," Exp. Eye Res., vol. 52, 1991, pp. 27- 39.
 L. Pitk├ñnen, V. Ranta, V. H. Moilanen and A. Urtti, "Permeability of Retinal rigment epithelium: effects of permeant molecular weight and lipophilicity," Invest. Ophthalmol. Vis. Sci. vol. 46,2005, pp. 641-646.
 D. Maurice,"Review: practical issues in intravitreal drug delivery," J Ocul Pharmacol Ther. Vol. 17(4), 2001, pp. 393-401.